Restoring blood coagulation in patients
taking Factor Xa Direct Oral Anticoagulants
(FXa-DOACs)

About VarmX

Our focus lies in the development of a breakthrough, swift-acting, and convenient universal bypassing agent that restores blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs).

We aim to stop severe bleeding and eliminate bleeding risk during surgery in patients taking FXa DOACs.

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs

Portfolio

News & events

All news
  • Management TeamNews

VarmX recognised with two prestigious industry award nominations

Nominated for the 2026 Prix Galien USA “Best Startup” Award, and shortlisted with partner CSL for “Deal of the Year”...

  • News

VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX-C001 in urgent surgery

First participant enrolled: EquilibriX-S (NCT07288489), a landmark registrational Phase 3 study of VMX-C001 vs usual pharmacologic care in patients taking...

All news